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Introduction
Th e potential therapeutic beneﬁ ts of recombinant human 
erythropoietin (rhEPO) and its synthetic derivatives in 
critical care medicine have recently been reviewed in 
various journals [1-3] and even occasioned impassioned 
correspondences [4,5]. Th e results of pre-clinical trials 
suggest that rhEPO could be used not only to ameliorate 
anemia, but also to limit organ injury/dysfunction 
associated with stroke, myocardial infarction, trauma, 
hemorrhage and sepsis. However, despite the promising 
pre-clinical results, most recent clinical trials have not 
shown clear beneﬁ ts, and, in some patients, EPO-aggra-
vated morbidity and mortality was even reported. Since 
the 1990s, rhEPO has been successfully used to treat 
chronic kidney disease (CKD)-related anemia, but a 
subset of approximately 10% of these patients does not 
adequately respond to rhEPO therapy [6]. Th is condition 
is referred to as ‘EPO resistance’, which is characterized by 
either a need for higher doses of EPO to maintain the 
recommended hemoglobin (Hb) or even a lack of response 
to EPO at all [6]. Th e conﬂ icting results of the recent 
clinical trials that evaluated the cytoprotective eﬀ ects of 
rhEPO beg the question of the applicability of our pre-
clinical models in the clinical setting. Th e following 
viewpoint uses rhEPO as an example to highlight the 
possible pitfalls in current practice using young healthy 
animals for the evaluation of therapies to treat patients of 
variable age and underlying chronic co-morbidity.
Erythropoietin and its receptor
While EPO is mainly produced in the peri-tubular cells 
of the kidney in response to hypoxia, low levels of EPO
mRNA have also been reported in the central nervous 
system, lungs and spleen. EPO is well-known as a 
regulator of erythrocyte production to optimize tissue 
oxygenation: A drop in local O2 tension leads to the 
stabilization of hypoxia inducible factor, which binds to 
the hypoxia-responsive elements of the EPO gene 
activating its transcription. EPO needs a receptor 
(EPO-R) to perform its function, and this EPO-R is 
expressed on erythroid cell progenitors and in a variety of 
tissues and cell types  - for example, the brain, retina, 
heart, kidney, vascular smooth muscle cells, myoblasts 
and vascular endothelium. Administration of EPO up-
regu lates EPO-R expression and increases endothelial 
nitric oxide (NO) production. EPO-R expression was also 
conﬁ rmed in primary human kidney tubular epithelial 
cells, in rat cortical and medullary tubules as well as in 
porcine wound healing ﬂ uid, granulation tissue, and 
kidney [7-9]. However, children with acute kidney injury 
presented with elevated EPO-R expression in the kidney 
but decreased EPO plasma levels [10], and diﬀ erential 
regulation of EPO-R expression in renal tissue biopsies 
from young, healthy versus older, co-morbid swine was 
reported [11].
Accruing evidence suggests that EPO exerts tissue-
protective properties via a diﬀ erent heteroreceptor 
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EPO-R isoform, which has been proposed to comprise a 
classic EPO-R homodimer and the cytokine β-common 
receptor (βcR). Gorio and colleagues [12] demonstrated 
both the association of the βcR subunit and the EPO-R as 
well as the need for the heteroreceptor combination for 
the recovery of motor function after spinal cord 
compression injury. Saqib and colleagues [9] showed in a 
porcine model of wound healing that EPO was associated 
with an increase of granulation tissue, and demonstrated 
higher expression and the co-localization of EPO-R and 
βcR in the cellular constituents of the granulation tissue. 
It is noteworthy that the βcR is involved in EPO-mediated 
endothelial nitric oxide synthase (eNOS) activation in 
endothelial cells [13]: both EPO- and eNOS-derived NO 
inhibit neo-intima formation and improve re-endo thelia-
lization in a dose-dependent manner [14]. Furthermore, 
synthetic EPO derivatives like carbamylated EPO (cEPO) 
provided additional insight into the properties of the 
EPO hetero-receptor complex: cEPO does not bind to 
the hematopoietic EPO-R and thus does not increase the 
hematocrit, but exerted cytoprotective eﬀ ects in cerebral 
infarction, spinal cord trauma, and kidney ischemia/
reperfusion (I/R) injury [15]. Recently, cEPO was even 
reported to more eﬀ ectively reduce kidney inﬂ ammation 
in brain-dead rats than rhEPO [16], and a newly developed 
cEPO-FC fusion protein was at least as protective as 
rhEPO in a porcine aortic balloon occlusion-induced 
spinal cord I/R injury [17]. At present, four clinical trials 
have evaluated the safety and pharmacokinetics of cEPO 
for acute ischemic stroke (ClinicalTrials.gov identiﬁ ers 
NCT00870844 and NCT00756249), in advanced kidney 
cancer (NCT00035243) as well as in patients with the 
Friedreich´s ataxia (NCT01016366): so far results are not 
yet available.
Erythropoietin pre-clinical studies
Th e ﬁ rst tissue-protective eﬀ ects of EPO were observed 
in animal models of ischemic injury in the brain and 
spinal cord. Later reports followed of EPO’s protective 
role in models of myocardial infarction, where it 
apparently has a very large range of applicability: before 
ischemia, acutely during reperfusion and even after 
myocardial ischemia. In all these conditions, chronic 
administration led to a reduction of myocardial injury 
and remodeling. In rodent [15,16,18-27], large animal 
[17,27-41] and primate [42] models, EPO protected 
against I/R injury in the central nervous system 
[17,26,27], the heart [20,21,29-37], and the kidney [22-
26,38-42]. Tables 1 to 3 present major pre-clinical studies 
documenting the tissue-protective eﬀ ects of EPO in 
rodent and large animal models. It is interesting to note 
that in the majority of these studies, EPO had more 
pronounced therapeutic eﬀ ects in rodents than in large 
animal models. One porcine study even reported that 
EPO failed to exert any cardioprotective eﬀ ect [29]. 
Clearly, the less eﬃ  cacy in large animals may be due to 
the lack of resuscitative measures in small animal 
experiments. Nonetheless, the pleiotropic eﬀ ects of EPO 
are well-established in many pre-clinical studies, through 
the use of commercially available rhEPO, synthetic EPO 
derivatives or mimetic peptide analogs such as ARA-290. 
Th erefore, let us now take a look at the recent clinical 
trials.
Erythropoietin clinical trials
Corwin and coleagues’ report on the CRIT Study [43] 
examined the incidence of anemia and red blood cell 
transfusions in critically ill patients and determined that 
trauma patients were more likely to be transfused than 
non-trauma patients. Four separate randomized, placebo-
controlled studies using rhEPO in this context were 
conducted, which enrolled 160, 1,302, and 1,460 anemic 
(total Hb concentration of <12 g dL-1) critically ill patients 
[44-46] and 86 ‘long-term acute care patients’ [47]. Th e 
ﬁ rst two trials demonstrated a reduction of transfusion 
requirements, and the second even had an increased 
survival rate in the treatment arm. Due to a lack of data 
of speciﬁ c trauma events that could aﬀ ect the outcome, 
however, a deﬁ nitive assessment was impossible. Interest-
ingly, in the third trial no transfusion reduction was 
observed with treatment despite the increase in Hb 
content. Furthermore, there was a clinically signiﬁ cant 
increase in thrombovascular events in rhEPO-treated 
patients in comparison to vehicle [44,45]. Finally, the 
most recent long-term trauma outcome study evaluating 
the role of rhEPO in anemic (Hb <12  g  dL-1) trauma 
subjects found no diﬀ erences in physical function or 
safety between the treatment and control arms [46].
Ehrenreich and colleagues [48] showed promising 
neuro protective eﬀ ects of rhEPO in a pilot study of 
ischemic stroke. Th e subsequent large double-blind, 
placebo-controlled, randomized muticenter rhEPO 
stroke trial not only failed to show any neuroprotective 
beneﬁ t, but, contrary to all expectations, patients treated 
both with rhEPO and tissue plaminogen activator 
presented with increased intracerebral hemorrhage and 
mortality [49]. Yip and colleagues [50] also tried to assess 
the beneﬁ ts of rhEPO after acute ischemic stroke: they 
reported an increase in endothelial progenitor cells and 
decrease of 90-day major adverse neurological events. 
Th e commentary by Minnerup and colleagues [51] 
highlighted the fact that the two trials focused on diﬀ er-
ent primary endpoints: a reduced incidence of recur rent 
strokes at day  90 does not necessarily imply improved 
neurological function.
Th e two trials on EPO eﬀ ects on spinal cord injury, 
Evaluation of Tolerability and Eﬃ  cacy of EPO Th erapy in 
Spinal Shock (NCT00220675) and EPO Spinal Cord 
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Compression Randomized Trial (NCT00220675) were 
both terminated prematurely. An additional trial looking 
at the beneﬁ ts of rhEPO without prophylactic anti-
coagulation in elective spinal surgery noted an increase 
in deep vein thrombotic events. Th e study concludes with 
the recommendation to add anti-thrombotic prophylaxis 
to rhEPO in the surgical setting [52].
Th e Reduction of Infarct Expansion and Ventricular 
Remodeling with Erythropoietin after Large Myocardial 
Infarction (REVEAL) trial enrolled 222 patients and 
showed unchanged infarct size after treatment compared 
to vehicle. Interestingly, in the treatment arm, older 
patients (aged >70 years) even presented with a doubling 
in infarct size in the ﬁ rst week [53].
In the setting of acute kidney injury (AKI) a study of 71 
patients undergoing elective coronary artery bypass graft 
surgery had a reno-protective eﬀ ect [54], whereas the 
larger (n = 162) Early Intervention in Acute Renal Failure 
(EARLYARF) trial, evaluating rhEPO therapy in a 
heterogeneous group of ICU patients, found no such 
eﬀ ects [55]. Another clinical trial (Recombinant Human 
Erythropoietin use in Intensive Care Unit Patients: Does 
it prevent acute renal failure; NCT00676234) recruited 
80 patients and was completed in 2009, but no data are 
available so far. Finally, a very recent follow-up report 
from the aforementioned trial [55] on the incidence of 
end-stage renal disease and mortality showed that rhEPO 
reduced all-cause mortality and development of end-
stage renal disease in patients that had previously 
suﬀ ered from AKI [56]. Th is subset of patients with AKI 
comprised 21 patients, 14 in the placebo group and 7 in 
the rhEPO group. Interestingly, patients in the placebo 
group were older (67 to 84 years; 10 of the 14 patients 
were >70 years) than those in the rhEPO group (58 to 
75 years; 3 of the 7 were >70 years). It may be too early to 
make deﬁ nitive conclusions from these data, but the 
Table 1. Pre-clinical data on eff ects of rhEPO and cEPO in models of central nervous (cerebral and spinal cord) I/R injury
Species Model Dose (IU·kg-1) Protocol Outcome Histology Apoptosis Reference
Rat Stroke: embolic 
middle cerebral 
artery occlusion
500, 1,150, 
or 5,000
6, 24, and 48 h 
post-embolus
50% improvement of 
foot-fault test and modifi ed 
Neurological Severity Score
Dose-dependent 
reduction of infarct 
volume (17, 28, 36%); 
3% reduction in 
activated microglial 
cells
31% drop in TUNEL 
cells
[18]
Rat Stroke: left 
internal carotid 
artery occlusion
5,000 Immediately, 
12, and 24 h 
after ischemia
20% improved ‘corner test’; 
reduced oxidative stress 
and infl ammation
Reduced infarct 
size (7 versus 
25%); enhanced 
angiogenesis
50% drop in TUNEL 
cells; increased Bcl 
expression
[19]
Swine Aortic balloon 
occlusion spinal 
cord ischemia/ 
reperfusion injury
5,000; 
cEPO-FC 
50 μg·kg-1
30 minutes 
before, over 4 h 
after ischemia
Improved lower limb 
neurological function 
(response score: vehicle 0, 
rhEPO 4, cEPO-FC 4) and 
motor evoked potentials 
(vehicle 0, rhEPO 10, cEPO-
FC 63% recovery); reduced 
oxidative stress (blood 
isoprostane levels)
Less NISSL-positive 
neurons (thoracic: 
vehicle 27, rhEPO 5 
cEPO-FC 8%; lumbar: 
vehicle 26, rhEPO 8, 
cEPO-FC 7%)
No TUNEL and 
caspase-3-positive 
neurons
[17]
Swine Hypothermic 
circulatory arrest
500 60 minutes 
before cardiac 
arrest
No diff erence in mortality 
or neurological outcome; 
lower glutamate and 
glycerol levels (cerebral 
microdialysis)
No diff erence in brain 
histology
Apoptotic index 
(TUNEL) 0.0 versus 
0.99
[27]
Swine Deep 
hypothermic 
circulatory arrest
500 24 and 3 h 
before, 24 h 
after cardiac 
arrest
No diff erence in mortality 
or neurological outcome; 
lower S-100β, lactate, and 
glycerol levels (cerebral 
microdialysis)
No diff erence in 
histology; reduced 
brain infarction (2/8 
versus 8/8)
ND [28]
Swine Aortic balloon 
occlusion spinal 
cord ischemia/ 
reperfusion injury
300 30 minutes 
before, over 4 h 
after ischemia
No diff erences in motor 
evoked potentials
Less NISSL-positive 
neurons in thoracic 
(25 versus 38%) spinal 
cord, lumbar spinal 
cord no diff erence
Thoracic spinal 
cord: less TUNEL 
cells (18 versus 65); 
lumbar spinal cord: 
no diff erence
[39]
cEPO, carbamylated erythropoietin; I/R, ischemia/reperfusion; ND, not determined; rhEPO, recombinant human erythropoietin; TUNEL, terminal deoxynucleotidyl 
transferase dUTP nick end labeling.
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Table 2. Pre-clinical data on eff ects of rhEPO and EPO analogs in models of myocardial I/R injury 
Species Model Dose (IU·kg-1) Protocol Outcome Histology Apoptosis Reference
Rat Coronary artery 
ligation
8,000 Immediately, or 
3 weeks after 
artery ligation, 
once a week 
over 3 weeks
Decrease in LVDEP by 
27 to 38%, improved 
contractility and 
relaxation, no diff erence 
in mortality
Early treatment: 
reduced infarct 
size (23 to 30%); 
late treatment: 
no diff erence, but 
increased capillary 
density (39 to 48%)
ND [20]
Mouse Coronary artery 
ligation
2,500 24 h and 30 
minutes before, 
or immediately 
after ligation
nNOS-dependent 
reduction of ventricular 
arrhythmia
50% reduction of 
infarct size
ND [21]
Swine Coronary artery 
occlusion
500 24 h and 90 
minutes, or 90 
minutes alone 
before ischemia
No cardioprotective 
eff ects
Infarct size not 
diff erent
ND [29]
Dog Coronary artery 
ligation
1,000 Immediately, 
6 h, or 1 week 
after ischemia
Less ventricular fi brillation 
during reperfusion (0 
versus 50%)
Reduced infarct size 
(8 versus 40%)
Less TUNEL cells (50%) [30]
Dog Coronary artery 
ligation
1,000 Bolus 
immediately, 
6 h, or 1 week 
after ischemia
Increase in LVEF (42 versus 
49/56%), improved 
capillary density and 
myocardial blood fl ow 
(by 50%)
Reduced infarct size 
(10 versus18%)
ND [31]
Swine Chronic 
myocardial 
ischemia
300 Endocardial 
injection 
2 weeks 
after start of 
ischemia
LVEF 64 versus 55%; 
2.2 versus 3.3 hypokinetic 
segments
Reduced ischemic 
surface (19 versus 
41%), less fi brosis 
(8 versus 27%)
ND [32]
Swine Coronary artery 
occlusion
Darbepoitein 
30 μg·kg-1
At time of 
reperfusion
Regional functional 
improvement
No reduction in 
infarct size, less 
fi brosis (7 versus 10%); 
increased capillary 
density (106 versus 
89%)
ND [33]
Swine Chronic 
myocardial 
ischemia
300 Endocardial 
injection 
2 weeks 
after start of 
ischemia
LVEF 66 versus 55%; 
2.2 versus 3.3 hypokinetic 
segments
Less fi brosis 8 versus 
27%
TUNEL cells not 
detected
[34]
Swine Coronary artery 
occlusion
EPO analog 
0.9/0.4 μg·kg-1
At time of 
reperfusion, 
once weekly 
over 4 weeks
LVEF 39 versus 33%; 
improved wall motion 
score
Less fi brosis 7 versus 
12%, 50% increase in 
peri-infarct capillary 
density, infarct size not 
diff erent
ND [35]
Swine Coronary artery 
ligation
500 30 minutes 
and 24 h after 
ischemia
Fractional shortening 
55 versus 36% at day 14; 
reduced oxidative stress 
and enhanced eNOS 
expression
25% reduction of 
infarct size; enhanced 
angiogenesis
Less TUNEL cells 
(50%), less caspase-3 
expression
[36]
Swine Coronary artery 
embolization
200 Every 2 days 
over 8 days
Cardiac function not 
diff erent; increased VEGF 
and angiogenesis
Infarct size and fi brosis 
not diff erent
ND [37]
EPO, erythropoietin; LVDEP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction; ND, not determined; nNOS, neuronal nitric-oxide synthase; 
rhEPO, recombinant human erythropoietin; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; VGEF, vascular endothelial growth factor.
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Table 3. Pre-clinical data on eff ects of rhEPO and cEPO in models of kidney I/R injury
Species Model Dose (IU·kg-1) Protocol Outcome Histology Apoptosis Reference
Rat Bilateral renal 
artery occlusion
300 30 minutes 
before 
ischemia, or 
5 minutes 
before, or 
30 minutes 
after start of 
reperfusion
Less rise in creatinine (150 
to 170 versus 220 μmol·L-1) 
and higher creatinine 
clearance (0.3 versus 
<0.1 ml·minute-1);
50% lower 
histopathology score
Less TUNEL cells 
(50%), less caspase-3 
expression 
[22]
Mouse Bilateral renal 
artery occlusion
1,000 Daily over 
3 days or 
immediately 
before 
ischemia
Less rise in urea and 
creatinine (pre-treatment: 
200 versus 350/0.8 
versus 2.0 mg·dL-1; 
pre-reperfusion: 300 
versus 350/1.5 versus 
2.0 mg·dL-1mg·dL-1); 
attenuated tissue 
infl ammation and lipid 
peroxidation
Reduced tubular 
dilatation, swelling 
and necrosis
ND [23]
Rat Unilateral renal 
artery occlusion
5,000 30 minutes 
before 
ischemia
Lower serum creatinine 
(0.04 versus 0.21 mmol·L-1) 
and urea (13 versus 41 
mmol·L-1); enhanced 
tubular regeneration 
Ameliorated tubular 
cast formation
Less ascending limb 
apoptosis (2.2 versus 
6.5%)
[24]
Rat Bilateral renal 
artery occlusion
500 20 minutes 
before 
ischemia
Less rise in blood urea 
(381 versus 193 mg·dL-1) 
and creatinine (6.7 versus 
2.3 mg·dL-1); attenuated 
NFκB p65 
50% reduction of 
tubular necrosis
Less TUNEL positive 
cells, less Bax 
expression
[25]
Rat Bilateral renal 
artery occlusion
5,000 At time of 
ischemia (T0), 
or 6 h post-
ischemia (T6)
Less rise in serum 
creatinine (T(0): 0.04 
versus 0.17, T(6): 0.03 
versus 0.17 mmol·L-1); 2- to 
3-fold higher mitosis in 
cortex and outer medulla
Reduced tubular 
luminal casts, no 
attenuation of 
necrosis
50 to 70% less TUNEL 
cells
[26]
Swine Renal artery 
occlusion after 
nephrectomy
1,000 At time of 
ischemia, daily 
over 5 days of 
reperfusion
Ameliorated creatinine 
clearance at 12 h: 95 
versus 68/74% at 12 and 
36 h
Less necrotic cells Less caspase-3 
positive tubular cells
[38]
Swine Aortic balloon 
occlusion
300 30 minutes 
before 
occlusion, over 
for 4 h during 
reperfusion
Improved creatinine 
clearance (66 versus 
48 ml·minute-1) and lower 
fractional Na excretion 
(8 versus 12%)
Histology not diff erent TUNEL not diff erent [39]
Swine Unilateral renal 
artery occlusion
5,000 1 h before 
clamping
Less (25 versus 75%) fall in 
glomerular fi ltration rate, 
no diff erence in fractional 
Na excretion
ND No diff erence in 
caspase-3
[41]
Primate Unilateral renal 
artery occlusion
2,400 5 minutes 
each before 
clamping and 
declamping
Lower creatinine, urea, 
and cystatin C (7 versus 
3, 60 versus 40, 1.8 
versus 2.5 mg·dL-1); lower 
IL-6 levels (50 versus 
100 pg·L-1)
Ameliorated 
congestion, cell 
infi ltration
Less tubular TUNEL 
cells
[42]
cEPO, carbamylated erythropoietin; I/R, ischemia/reperfusion; ND, not determined; NF-κB, nuclear transcription factor κB; rhEPO, recombinant human erythropoietin; 
TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.
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REVEAL study suggests putative harm by rhEPO in 
patients aged over 70 years [53]. Whether or not age (and 
the presence or not of underlying CKD) may provide 
useful information deﬁ ning who may be best served by 
rhEPO therapy warrants further investigation.
Chronic kidney disease and erythropoietin resistance
In an eﬀ ort to understand why results from recent clinical 
trials to treat AKI are mixed, let us take a look at renal 
disease and CKD-related co-morbidity and EPO resis-
tance. Renal disease is associated with a graded increase 
in both inﬂ ammatory and oxidative markers: i) patients 
with CKD presented with increased blood lipid hydro-
peroxide, oxidized low density lipoproteins, F2-iso-
prostanes, TNF-α, IL-6, and IFN-γ when compared with 
patients with normal kidney function [6,57]; ii) in sub-
group studies from clinical trials, patients with CKD 
responded diﬀ erently to pharmaceutical interventions 
compared to patients with normal kidney function [58]; 
iii) atherosclerosis, which is characterized by an increase 
in low density lipoproteins, a decrease in high density 
lipoproteins, oxidative stress, endothelial dysfunction 
and inﬂ ammation, is prevalent in CKD, increases with 
age, and is the main risk factor for cardiovascular disease 
[57]. Finally, atherosclerosis is also associated with reduced 
NO bioavailability [59], and the constitutive production 
of NO has been shown to be attenuated in patients with 
CKD [60].
Th e mechanisms underlying EPO resistance are poorly 
understood and most likely multi-factorial, since endo-
genous EPO levels tend to be higher in these patients 
than in control subjects [61]. Age and the manifold 
aspects of ageing add to this complexity: in a geriatric 
cohort higher EPO blood levels were directly related to 
mortality [6]. Nevertheless, there is general consensus 
that inﬂ ammation and oxidative stress are key players 
[6,62,63]: the pro-inﬂ ammatory cytokines IL-6, IFN-γ, 
and TNF-α may antagonize the actions of EPO by 
inhibiting erythroid progenitor cells, activating suppres-
sor of cytokine signaling, down-regulating EPO-R 
expression and generating reactive oxygen species that 
lead to lipid peroxidation of red cell membranes [6,62,63]. 
Moreover, EPO activates eNOS, which is considered to 
be critical for its tissue protective eﬀ ects: genetic eNOS 
deletion is associated with a loss of response of 
endothelial progenitor cells to EPO stimulation ex vivo 
[64], and in vivo EPO not only failed to exert any vaso-
protective eﬀ ects but even worsened remodeling after 
vascular injury [59]. In rats with heminephrectomy-
induced polycythemia, EPO aggravated arterial hyper-
tension and only partially attenuated the fall of the 
glomerular ﬁ ltration rate caused by non-selective NO 
synthase inhibition with L-NAME (NG-nitro-L-arginine-
methyl ester) [65].
Animal models
Animal models that use young and healthy animals are 
essential for the understanding of basic pathophysio-
logical mechanisms. Any investigator will try to reduce 
inter-individual variation as much as possible and choose 
animals of the same sex, age and strain in order to control 
for physiology and establish reproducible and deﬁ ned 
conditions. Such models are valuable inasmuch as they 
provide unique insights into the pathophysiology of 
speciﬁ c experimental scenarios and even identify novel 
therapeutic targets. However, one of the problems with 
research conducted in naive animals is that a dramatic 
beneﬁ t is often observed that cannot be reproduced in 
the clinical study: a systemic review of pre-clinical and 
clinical trials concluded that the discordance was due, at 
least in part, to the failure in the pre-clinical trial to 
properly mimic the clinical disease [66]. A single factor 
such as age may have major eﬀ ects: antibiotic therapy in 
cecal ligation puncture-induced murine sepsis halved 
mortality in young animals, while this intervention had 
no beneﬁ t in older mice [67]. In contrast to the epi-
demiology in patients, who usually present with variable 
co-morbidity, all data on EPO-related organ protection 
against I/R injury originate from models investigating 
young and healthy animals. Th is limitation thus assumes 
importance in light of failed clinical studies in compari-
son to pre-clinical trials. We found a similar lack of 
protec tion against I/R injury of rhEPO in adult swine 
with ubiquitous atherosclerosis resulting from familial 
hyper cholesteremia [11] and an atherogenic diet (so-
called familial hypercholesteremia Bretoncelles Meishian 
(FMB) swine) when compared to otherwise young and 
healthy animals [17,39]. Th ese FBM swine present with 
hypercholesteremia and increased markers of oxidative 
stress, while creatinine clearance, blood levels of NO 
metabolites, and renal tissue expression of EPO-R are 
reduced - that is, this strain shows a biomarker pattern 
comparable with that found in patients with hyper-
cholesteremia-induced atherosclerosis [11,68]. As age-
matched wild-type and young (6  months) FBM swine 
without the atherogenic diet showed the same EPO-R 
expression as young and healthy animals, the reduced 
EPO-R expression may not only provide a plausible 
explanation for ineﬀ ectiveness of EPO in this model, but 
also potentially hint at one of the underlying causes of 
‘EPO resistance’.
Conclusion
Th e promise of pre-clinical data on organ-protective 
eﬀ ects of rhEPO has not been matched by successful 
clinical trials. Th e results from the animal models using 
young, healthy animals provide us with very important 
pathophysiological mechanistic information. Th e 
mechanisms may apply, but often other factors, including 
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gender, age, and, in particular, co-morbidity, confound 
the therapeutic strategy. Th e distinct contrast in the 
experimental results in kidney I/R injury between the 
young, healthy swine and the FBM swine might help to 
underline the importance of pre-existing co-morbid 
conditions for the design of pre-clinical experimental 
models. Th ese results may not only oﬀ er a potential 
expla nation for the diﬀ ering results of receptor expres-
sion in human samples, which may be reconciled when 
the etiology of disease of the donors are better under-
stood, but also suggest that animal models that more 
closely mimic the human disease conditions may provide 
better guidance for future therapeutic strategies. Finally, 
it is tempting to speculate whether pre-existing impair-
ment of kidney function and decreased renal tissue 
EPO-R expression may explain the controversial eﬀ ects 
of rhEPO in clinical trials.
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